Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG (“CAIAC”) for the Company’s remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), for gross proceeds of PLN 6,700,000 (CAD2,308,000).

20201222 – HBP Press Release – HIO Closes HIO Divestiture